Executive Director, National Payer Accounts

Overview

The Executive Director, National Payer Accounts will lead a field team accountable for formulary coverage access with the national payer organizations and their largest downstream regional account clients. Supporting the strategy of the Market Access team and execution of objectives for the payer customers. Collaborating with leaders in market access, therapeutic areas, insight, access strategy, finance, and medical affairs to align approaches to our largest customers. Coordinating and leading our approach across the National Payer Accounts and their largest regional clients for our product portfolio.

Responsibilities

• Lead, develop, and motivate a high-performing team of Sr. Directors, National Payer Accounts to deliver results aligned with function and organizational goals.
• Cultivate direct relationships with senior leaders at key accounts to strengthen strategic partnerships.
• Coordinate activities of the National Payer Account team in cooperation with the patient services and external partners to minimize barriers to access on a patient specific basis
• Identify opportunities for pull-through and improved account access in partnership with other field and home-office teams.
• Lead cross functional teams in developing and executing access-focused National Payer Account Plans in cooperation with relevant functions (Sales, Medical Affairs, Marketing and Pricing).
• Partner with Market Access colleagues and brand teams to create an impactful and strategically aligned tactical plan for the payer segment to successfully support access and awareness of Stemline products.
• Identify, create, and execute specific programs and services to support best in class market access support.

• Partner with Contract Strategy and Pricing team to develop and implement payer contracting strategies.
• Lead strategic direction and accountability for contract negotiations to support Stemline access goals, including discounts, rebates, administrative fees, and innovative contracting constructs, in accordance with Pricing Committee Guidelines and corporate objectives.
• Lead strategic planning exercises to inform the long-term Stemline access strategy including presentations and alignment with executive leadership
• Develop payer strategy for pipeline programs and provide input to lifecycle management activities as needed.
• Lead internal reviews to ensure cross-functional teams are aware of ongoing payer activities and mitigation plans for any challenges or risks.
• Maintain a deep understanding of the payer environment, including PBMs, private payers, and government channels and educate internal partners as required.

• Set clear performance objectives/expectations and provide ongoing coaching and development of direct reports including concrete business objectives.
• Create KPIs that measure success and align with Stemline business objectives.
• Continuously review, evaluate and recommend improvements to organization to enable higher performance.
• Manage field team expenses according to budget.
• Ensure all field team activities are conducted compliantly.
• Up to 30% travel, including customer meetings, conferences, and internal cross-functional workshops.

Qualifications

• Bachelor's degree required, advanced business or science degree desirable.10+ years of pharma/biotech access-focused experience, with at least 5+ years with management experience.
• 5+ years working directly with National Payers/PBMs (specifically in Oncology)
• Strong understanding of reimbursement (Buy & Bill) pathways, pharmacy-benefit management, Medicare (Parts A, B, C, D), Medicaid, and commercial payer dynamics
• Demonstrated success in finding the point of intersection between customer and business priorities
• Thorough understanding of market dynamics across multiple therapeutic areas (Oncology/Hematology preferred) and across various business segments
• Understanding of financial concepts and contracting issues, including legal and best price and ASP implications
• Understanding of specialty pharmacy networks and patient out-of-pocket dynamics
• Proactive, results oriented, self-starter motivated by the desire to do the right thing for the patients and their caregivers
• Excellent planning, organization and time management skills including the ability to support and prioritize multiple projects
• Strong oral and written presentation skills and executive presence.
• Proven ability to work in a fast-paced, highly visible and dynamic environment; able to work effectively with ambiguity and incomplete information.
• Ability to influence and lead across functions; operate in a matrix environment.
• Must be a highly cross functional team player that is willing to participle in activities that may not necessarily be in his/her core responsibilities
• Must adhere Stemline’s core values, policies, procedures and business ethicsOvernight travel of 30% may be required

Base Salary Range of $267,000 to $322,000. Menarini Stemline offers generous compensation and benefits packages, including Short and Long-Term Incentive Programs, Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees.  All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Italian pharma group's oncology division developing targeted cancer therapies and hematologic treatments. Based in Florence, Italy.

menarini.com